港股生物医药企业递表的热度仍在持续。 2025年12月21日，吉因加科技（绍兴）股份有限公司正式向香港联交所递交招股说明书，拟登陆香港主 板，建银国际、民银资本担任联席保荐人。公开资料显示，吉因加专注于AI驱动的多组学技术，将AI 能力深度嵌入生物标志物价值链各个核心环节，致力于通过技术创新推动精准诊断与药物研发的变革。 根据灼识咨询，吉因加构建了行业内最早的大规模多组学基线数据库之一。依托自主研发的多组学平 台，结合基础大模型与智能体AI，公司已形成从多组学生物标志物及靶点的发现、验证、产品开发到 商业化落地的全链条能力，核心业务覆盖精准诊断、药物研发赋能、临床科研与转化三大解决方案。 值得注意的是，就在递表港股前夕，吉因加于2025年11月28日宣布完成3亿元人民币D轮融资。此次融 资资金将主要用于AI多组学技术研发、创新管线拓展及全球服务网络深化，重点加速MRD监测、肿瘤 早筛等核心产品的临床转化进程。 截至目前，公司股东阵容已涵盖华大基因、爱尔医疗等产业资本，以及纪源资本、华盖资本、达晨、昌 平投资、松禾创业等知名投资机构，为其后续发展提供了坚实的资本支撑。 转型投入期能否破局？ 商业化落地层面，截至 ...

投资界12月1日消息，近日，国内领先的精准医疗企业吉因加科技（绍兴）股份有限公司（以下简称"吉 因加"）宣布完成3亿人民币的D轮融资。本轮融资由绍兴市越城区科创引智基金、北京昌平产业发展投 资基金等联合投资，资金将主要用于AI多组学技术研发、biomarker创新管线拓展及全球服务网络深 化，进一步强化公司在精准诊断、新药研发等应用场景的全链条服务能力，助力AI驱动的多组学技术 从科研加速迈向临床转化。 绍兴市越城区科创引智基金管理人表示："精准医疗是国家重点支持的战略性新兴产业，市场前景广 阔。吉因加在技术研发、临床转化等方面积累深厚，具备强劲的发展势能。此次投资是基于对企业核心 价值与行业发展趋势的坚定看好，未来将持续助力企业深耕赛道、拓展布局。" 北京昌平产业发展投资基金管理人昌发展表示："北京昌平正全力打造全球领先的'生命谷'，AI+精准医 疗是区域重点支持的前沿赛道，也是医疗健康领域新质生产力的重要组成。吉因加作为 AI 精准医疗领 域的领军者，在技术创新与商业化落地方面表现亮眼，其发展方向与昌平产业布局高度契合，通过此次 合作将共同推动精准医疗技术普及，赋能区域医疗健康产业高质量发展。" 吉因加总 ...

Core Viewpoint - The company has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for RMB 12.396 million, enhancing its strategic control over the regional high-end medical testing services in Southwest China [1] Group 1: Transaction Details - Wuhan Kangshengda has successfully won the bid for a 40% stake in Huaxi Kangshengda through the North Exchange public listing process [1] - The transaction was formalized on November 25, 2025, with a total consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the Southwest region, covering Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient and consistent execution of the overall strategy in the Southwest region [1] - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergistic effects between ICL-driven IVD product development and IVD service upgrades [1] Group 3: Management and Collaboration - The company will take full control over the management appointments, performance assessments, and resource allocation of Huaxi Kangshengda, improving the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the Southwest region [1] - This integration will strengthen the regional operational capabilities of the company [1]

Core Viewpoint - The company successfully acquired a 40% stake in Huaxi Kangshengda, enhancing its strategic position in the southwestern region of China and aligning with its overall business strategy [1] Group 1: Acquisition Details - Wuhan Kangshengda has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will strengthen the company's management over Huaxi Kangshengda's operations and strategic direction, ensuring efficient and consistent execution of the overall strategy in the southwestern region [1] Group 3: Operational Enhancements - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergies between ICL-driven IVD product development and IVD service upgrades [1] - The company will take full control of Huaxi Kangshengda's management appointments, performance assessments, and resource allocation, enhancing the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the southwestern region to strengthen regional integrated operational capabilities [1]

Core Viewpoint - The acquisition of a 40% stake in Huaxi Kangshengda by Wuhan Kangshengda is a strategic move to enhance the company's control over its operations and align with its overall business strategy in the southwestern region of China [1][2]. Group 1: Transaction Details - Wuhan Kangshengda successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1]. - Following the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the company [2]. Group 2: Strategic Importance - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [2]. - The full ownership will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient execution of the overall strategy in the southwestern region [2]. - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergy between ICL-driven IVD product development and IVD service upgrades [2].

Financial Performance - The company reported a total revenue of 110 million yuan for the first half of 2025, representing a year-on-year increase of 12.7% [1] - The net profit attributable to shareholders reached 14.0554 million yuan, up 21.16% year-on-year [1] - The gross profit margin was 56.34%, a slight decrease of 0.63% compared to the previous year, while the net profit margin increased by 7.51% to 12.83% [1] - The total of selling, administrative, and financial expenses was 37.2037 million yuan, accounting for 33.96% of revenue, down 6.17% year-on-year [1] - Earnings per share rose to 0.21 yuan, a 23.53% increase year-on-year [1] Business Model and Market Position - The company primarily relies on research and development and marketing to drive its performance [3] - It is a leader in the automation of urine analysis and has a significant market share in this segment, with competitors including Dirui, Mindray, and others [5] - The company has begun to focus on the consumer healthcare market, launching various POCT products aimed at women's health, child health, and other areas, indicating a potential growth direction [6] Technology and Innovation - The company is a pioneer in applying artificial intelligence and machine vision technology to medical urine specimen analysis, significantly improving testing accuracy and efficiency [7] - It has developed a large clinical specimen training database over 25 years, enhancing its algorithm for specimen recognition [7] Future Plans - The company is considering new projects and potential mergers and acquisitions to drive growth, as indicated in its 2024 annual report [8]